Gout
Joel Topf spoke with Bradley Marder of Amgen about gout studies at the NKF Spring Clinical Meetings 2025.
Researchers examined factors associated with adherence to the urate-lowering therapy allopurinol.
A study examined one medical center's adherence to gout management guidelines regarding use of ULT to lower uric acid levels.
A study examined whether systemic inflammation response index could be a predictive marker for gout risk.
A review and meta-analysis assessed the influence of SGLT2i therapy on clinically relevant hyperuricemic events.
A study examined the relationship between gout and kidney stones using NHANES data.
Researchers examined ULT and the risk of CKD progression among patients with impaired kidney function and gout.
What is the association of gout with CV disease and mortality risk in patients with type 2 diabetes and can CKD modify it?
The EMPA-KIDNEY trial examined the effects of SGLT2 inhibition on uric acid and gout in patients with CKD.
A study examined whether urate-lowering therapy (ULT) for gout might help delay progression of chronic kidney disease (CKD).
Researchers evaluated efficacy and safety of allopurinol versus febuxostat for gout in patients with stage 3 CKD.
Recognizing and managing concurrent gout and CKD is important for improving outcomes but can be difficult.
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.